Corbus pharmaceuticals holdings, inc. (CRBP)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flows from operating activities:
Net loss

-29,656

-26,580

-20,790

2,152

-26,234

-17,306

-14,601

-12,069

-11,695

-10,693

-6,965

-7,296

-7,465

-7,570

-5,346

-4,189

-2,892

-2,498

-2,253

-2,562

-1,535

Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Stock-based compensation expense

3,137

3,097

2,977

2,817

3,088

1,949

1,958

1,816

1,884

1,460

1,351

1,299

1,583

1,641

828

383

311

309

240

300

301

Depreciation and amortization

319

273

157

155

152

155

132

124

81

64

126

32

31

29

20

19

17

-

-

-

-

Foreign currency exchange gain (loss), net

126

-

-

-

-46

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Loss on foreign exchange

-

-

-

-

-

34

-4

31

9

-47

14

10

14

-

-

-

-

-

-

-

-

Operating lease right of use asset amortization

138

131

125

143

89

-

-

-

333

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent

-

-

-

-

-

-

-

-

-

886

31

-3

-1

75

0

0

0

-

-

-

-

Depreciation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

14

6

5

Changes in operating assets and liabilities:
Decrease in customer receivable

-

-

-

-

-

0

0

-6,250

-6,250

-500

500

0

-1,000

1,000

0

0

0

-

-

-

-

Increase in restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Decrease in prepaid expenses and other current assets

-128

1,039

449

-245

-10

-308

-76

-654

757

2,088

-124

-225

140

-

40

-199

98

-

-150

38

-59

Increase in contract asset

-1,762

-

-

-

-423

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Decrease in other assets

-70

-49

10

87

-8

23

-44

42

-18

-

-

-

-

-

-

-

-

-

-

-

-

Increase in other assets

-

-

-

-

-

-

-

-

-

-24

0

65

0

-

-

-

-

-

-

-

-

(Decrease) increase in accounts payable

-839

5,202

-1,934

-1,352

2,450

249

3,026

-564

1,192

-1,403

-71

589

0

442

805

838

-196

588

-541

1,080

-155

Increase in accrued expenses

1,110

-931

4,496

3,342

5,646

2,466

1,581

-55

1,120

2,182

-147

-156

-364

887

423

616

732

-653

825

96

44

Increase in deferred revenue

-

-

-

-

25,537

-

-

-

-

-

-296

-350

-1,293

624

257

-396

-396

-

-

-

-

Decrease in operating lease liabilities

-90

-14

707

300

-21

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash (used in) provided by operating activities

-27,601

-22,561

-17,086

-16,390

10,318

-14,064

-8,846

-5,556

-1,599

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from investing activities:
Increase in other long-term liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-6,636

-5,478

-3,051

-2,526

-2,514

-881

-2,483

19

-1,279

Purchases of property and equipment

463

1,291

1,194

183

73

249

105

675

1,269

580

45

41

40

96

69

121

65

93

4

14

1

Net cash used in investing activities

-463

-1,291

-1,194

-183

-73

-249

-105

-675

-1,269

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-40

-96

-69

-121

-65

-93

-4

-14

-1

Principal payments on notes payable

319

210

99

148

146

97

83

124

124

82

39

116

116

76

23

69

69

45

0

72

71

Proceeds from issuance of common stock

46,015

-0

80

102

40,494

10

39

146

11,856

37,512

8

20

41,349

1,463

179

15,055

0

509

6,417

4,339

62

Issuance costs paid for common stock financings

2,762

0

5

145

2,420

0

19

67

603

2,251

26

40

621

63

0

0

0

-

-

-

-

Principal payments under capital lease obligation

-

0

0

0

0

1

1

1

0

0

0

0

0

0

0

0

1

-

-

-

-

Net cash provided by financing activities

42,934

752

-24

-191

37,926

403

-64

-47

11,128

-

-

-

-

-

-

-

-

-

-

-

-

Net increase in cash and cash equivalents

14,869

-23,100

-18,305

-16,764

48,171

-13,910

-9,017

-6,279

8,259

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

40,611

1,671

155

14,985

-70

162

6,417

4,266

-9

Net increase in cash, cash equivalents, and restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

33,934

-

-

-

-

-

-

-

-

Net increase (decrease) in cash, cash equivalents, and restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,650

-

-

-

-

Net increase in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,929

4,271

-1,290

Supplemental disclosure of cash flow information and non-cash transactions:
Cash paid during the period for interest

8

8

14

4

1

2

5

0

1

1

8

1

1

-

-

-

-

-

-

-

-

Fair value of warrant issued in connection with Investment Agreement

-

-

-

-

-

0

0

0

6,215

-

0

0

0

-

-

-

-

-

-

-

-

Stock issuance costs included in accounts payable or accrued expenses

200

-

-

-145

151

-

-

-119

127

-

-

-

-

-

-

-

-

-

-

-

-

Right of use assets obtained in exchange for lease obligations

-

-

-

-

5,928

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Assets acquired under capital lease obligation

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

11

-

-

-

-

Purchases of property and equipment included in accounts payable or accrued expenses

-

-853

970

190

69

-91

57

-472

507

579

0

0

0

20

8

-107

112

-

-

-

-

Write off of fully amortized leasehold improvements

-

-

-

-

-

0

0

0

191

-

0

0

0

-

-

-

-

-

-

-

-

Cash paid during the period for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2

6

-

-1

0

0

Unpaid stock issuance costs

-

-

-

-

-

-

-

-

-

-

-

-18

44

-

-

0

0

-

-

-

-